Critical consumer protections from surprise medical bills face their latest test; a new legislative package seeks to address hospital consolidation; patent abuse keeps the price of inhalers artificially high; and, Medicare-eligible beneficiaries continue to choose Medicare Advantage plans.
Critical consumer protections from surprise medical bills face their latest test; a new legislative package seeks to address hospital consolidation; patent abuse keeps the price of inhalers artificially high; and, Medicare-eligible beneficiaries continue to choose Medicare Advantage plans.
As we gather to celebrate Independence Day, we wanted to take a moment to wish our Health Action Network community a Safe and Happy Fourth of July!
Critical consumer protections from surprise medical bills face their latest test; a new legislative package seeks to address hospital consolidation; patent abuse keeps the price of inhalers artificially high; and, Medicare-eligible beneficiaries continue to choose Medicare Advantage plans.
How some private equity interests are negatively impacting rural communities; drugmakers invest heavily…in their shareholders; analysis shows broad coverage of insulin products in Medicare Part D; and, clinical waste drives excess healthcare spending.
The majority of hospitals fail to comply with price transparency rules; new prescription drugs come with increasingly higher price tags; the No Surprises Act has already prevented millions of surprise medical bills; and, private equity interests continue to exact a heavy toll on our healthcare system.
Pharmacy Benefit Managers, or PBMs, work for YOU to connect you with the right medicine, at the right time and at the right price.
A new study reinforces the link between hospital prices and market share; unnecessary care is found to have persisted during the pandemic; stakeholders continue to urge for full implementation of consumer surprise medical billing protections; and, Medicare spending on prescription drugs outpaces R&D costs.
Hospitals look to historic rate increases to cover their costs; millions threatened with loss of coverage after the public health emergency ends; a reminder that drugmakers are ultimately the ones responsible for controlling insulin costs; and, stakeholders continue to defend the Medicare Advantage program.
A new report shines a light on hospital drug errors; elsewhere, trends point to broad geographic variation in hospital pricing; stakeholders rally to the defense of the critical Medicare Advantage program; and, a look at how Big Pharma exploits the patent system to its own benefit.